Journey Medical (DERM) news
Recent news
Fortress Biotech 2Q net revenue $18.7M
Fortress Biotech, Inc. (Nasdaq: FBIO) reported net revenue of $17.4 million for the second quarter of 2023, representing a 40% increase compared to $12.4 million in the first quarter of 2023. The company attributed this growth to strong performance from its marketed dermatology products and…
AInvest Wire · Aug 13, 2026Fortress Biotech 1Q net revenue $16.0M
Journey Medical Corporation, a commercial-stage pharmaceutical company under the Fortress Biotech umbrella, reported first-quarter 2026 net revenue of $16.0 million , representing a 21% year-over-year increase from $13.1 million in the same period of 2025. The growth was primarily driven by its…
AInvest Wire · May 14, 2026US FDA approves Journey Medical's drug for long-term skin condition
US FDA approves Journey Medical's drug for long-term skin condition The U.S. Food and Drug Administration (FDA) has recently granted approval to Journey Medical Corporation for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), a novel treatment option for inflammatory lesions of…
AInvest Wire · Nov 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.